Enterprise Value

319.4M

Cash

345M

Avg Qtr Burn

-18.2M

Short % of Float

9.40%

Insider Ownership

4.48%

Institutional Own.

98.85%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Zanidatamab (HER2) Details
Cancer, Solid tumor/s, Biliary Tract Cancer

BLA

Submission

Zanidatamab (HER2) Details
Cancer, Cholangiocarcinoma, Gastroesophageal adenocarcinomas

Phase 3

Data readout

Zanidatamab zovodotin (ZW49) Details
HER2-expressing cancers, Cancer, Non-small cell lung carcinoma

Phase 2

Update

Zanidatamab (HER2) + chemotherapy + tislelizumab Details
Cancer, Gastroesophageal adenocarcinomas, Cholangiocarcinoma

Phase 2

Update

Phase 1/2

Data readout